• 中国中文核心期刊
  • 中国科学引文数据库核心期刊
  • 中国科技核心期刊
  • 中国高校百佳科技期刊
高级检索

可溶性鸟苷酸环化酶激动剂的研究进展

胡立庆, 易锐, 李乾斌

胡立庆, 易锐, 李乾斌. 可溶性鸟苷酸环化酶激动剂的研究进展[J]. 中国药科大学学报, 2016, 47(5): 531-536. DOI: 10.11665/j.issn.1000-5048.20160504
引用本文: 胡立庆, 易锐, 李乾斌. 可溶性鸟苷酸环化酶激动剂的研究进展[J]. 中国药科大学学报, 2016, 47(5): 531-536. DOI: 10.11665/j.issn.1000-5048.20160504
shu
HU Liqing, YI Rui, LI Qianbin. Advances in soluble guanylate cyclase stimulator[J]. Journal of China Pharmaceutical University, 2016, 47(5): 531-536. DOI: 10.11665/j.issn.1000-5048.20160504
Citation: HU Liqing, YI Rui, LI Qianbin. Advances in soluble guanylate cyclase stimulator[J]. Journal of China Pharmaceutical University, 2016, 47(5): 531-536. DOI: 10.11665/j.issn.1000-5048.20160504
shu

可溶性鸟苷酸环化酶激动剂的研究进展

  • 中南大学药学院药物化学系

基金项目: 国家自然科学基金资助项目(No. 21102184,No.21172268)

Advances in soluble guanylate cyclase stimulator

摘要

    摘要
  • 摘要: 可溶性鸟苷酸环化酶(sGC)在体内是一种非常重要的信号转导酶，其活化后既可以激活NO-sGC-cGMP信号通路，又可以抑制TGF-β信号通路。cGMP是体内一种非常重要的第二信使，可以通过调节一些下游相关效应分子，如蛋白激酶G、cGMP依赖的磷酸二酯酶及cGMP门控离子通道，从而参与一系列的生理或病理反应，包括舒张血管、抑制血小板聚集，抑制细胞增殖等多种生理调节；TGF-β信号通路受到抑制后，可产生抑制组织纤维化与细胞增殖的生理作用。近年研究表明，通过直接激活sGC可治疗多种疾病。sGC激动剂作为一类新型药物，表现出了许多独特的优势。本文就sGC激动剂的作用机制及其最新研究进展做一综述，旨在为sGC激动剂类药物的研发提供参考。
    Abstract: Soluble guanylate cyclase is a key signal transduction enzyme in the body, which can activate the NO-sGC-cGMP signaling pathway and inhibit the TGF-β signaling pathway. cGMP is one of the most important second messengers and also involved in a series of physiological or pathological responses including vasodilation, inhibition of platelet aggregation, inhibition of cell proliferation and so on. When TGF-β signaling pathway is inhibited, it can inhibit issue fibrosis and cell proliferation. Recent studies have shown that sGC can be activated directly to treat a variety of diseases. As a new class of potential drugs, sGC stimulators have shown many unique advantages. Herein, the mechanism and the latest research progress of sGC stimulators are reviewed, which could provide a useful information for further research of sGC stimulators.
    • HTML全文
    • 参考文献(31)
  • [1] Derbyshire ER,Marletta MA.Structure and regulation of soluble guanylate cyclase[J].Ann Rev Biochem,2012,81:533-559.
    [2] Wang-Rosenke Y,Neumayer HH,Peters H.NO signaling through cGMP in renal tissue fibrosis and beyond:key pathway and novel therapeutic target[J].Curr Med Chem,2008,15:1396-1406.
    [3] Stasch JP,Pacher P,Evgenov OV.Soluble guanylate cyclase as an emerging therapeutic target in cardiopulmonary disease[J].Circulation,2011,123(20):2263-2273.
    [4] Stasch JP,Schlossmann J,Hocher B.Renal effects of soluble guanylate cyclase stimulators and activators:a review of the preclinical evidence[J].Curr Opin Pharmacol,2015,21:95-104.
    [5] Kotzki S,Roustit M,Arnaud C,et al.Anodal iontophoresis of a soluble guanylate cyclase stimulator induces a sustained increase in skin blood flow in rats[J].J Pharmacol Exp Ther,2013,346(3):424-431.
    [6] Friebe A, Koesling D. The function of NO-sensitive guanylyl cyclase:what we can learn from genetic mouse models[J].Nitric Oxide,2009,21(3/4):149-156.
    [7] Hill BG,Dranka BP,Bailey SM,et al.What part of NO don′t you understand? Some answers to the cardinal questions in nitric oxide biology[J].J Biol Chem,2010,285(26):19699-19704.
    [8] Castro NE,Kato M,Park JT,et al.Transforming growth factor β1(TGF-β1)enhances expression of profibrotic genes through a novel signaling cascade and microRNAs in renal mesangial cells[J].J Biol Chem,2014,289(42):29001-29013.
    [9] Seferian A,Simonneau G.Therapies for pulmonary arterial hypertension:where are we today,where do we go tomorrow[J]?Eur Respir Rev,2013,22(129):217-226.
    [10] Crosswhite P,Sun Z.Nitric oxide,oxidative stress and inflammation in pulmonary arterial hypertension[J].Hypertens,2010,28(2):201-212.
    [11] Baldi F,Fuso L,Arrighi E,et al.Optimal management of pulmonary arterial hypertension prognostic indicators to determine treatment course[J].Ther Clin Risk Manag,2014,10:825-839.
    [12] Liu Y.Renal fibrosis:new insights into the pathogenesis and therapeutics[J].Kidney Int,2006,69(2):213-217.
    [13] Judd E, Calhoun DA. Management of hypertension in CKD:beyond the guidelines[J].Adv Chronic Kidney Dis,2015,22(2):116-122.
    [14] Geschka S,Kretschmer A,Sharkovska Y,et al.Soluble guanylate cyclase stimulation prevents fibrotic tissue remodeling and improves survival in salt-sensitive Dahl rats[J].PLoS One,2011,6(7):e21853.
    [15] Gabrielli A,Avvedimento EV,Krieg T.Scleroderma[J].N Engl J Med,2009,360(19):1989-2003.
    [16] Beyer C,Distler O,Distler JH.Innovative antifibrotic therapies in systemic sclerosis[J].Curr Opin Rheumatol,2012,24(3):274-280.
    [17] Beyer C,Zenzmaier C,Palumbo-Zerr K,et al.Stimulation of the soluble guanylate cyclase(sGC)inhibits fibrosis by blocking non-canonical TGFβ signalling[J].Ann Rheum Dis,2015,74(7):1408-1416.
    [18] Stasch JP,Hobbs AJ.NO-independent,haem-dependent soluble guanylate cyclase stimulators[J].Handb Exp Pharmacol,2009(191):277-308.
    [19] Yasuda Y,Arakawa T,Nawata Y,et al.Design,synthesis,and structure-activity relationships of 1-ethylpyrazole-3-carboxamide compounds as novel hypoxia-inducible factor(HIF)-1 inhibitors[J].Bioorg Med Chem,2015,23(8):1776-1787.
    [20] Luo ZY,Jiang JT,Qin XH.The advancement in YC-1 anti-hepatocellular carcinoma mechanisms[J].Med Recapit,2011,17:2288-2290.
    [21] Chen YF,Lin YC,Chen JP,et al. Synthesis and biological evaluation of novel 3,9-substituted β-carboline derivatives as anticancer agents[J].Bioorg Med Chem Lett,2015,25(18):3873-3877.
    [22] Xiao J,Jin C,Liu Z,et al.The design,synthesis,and biological evaluation of novel YC-1 derivatives as potent anti-hepatic fibrosis agents[J].Org Biomol Chem,2015,13(26):7257-7264.
    [23] Soeiro-Pereira PV,Falcai A,Kubo CA,et al.BAY 41-2272 activates host defence against local and disseminated Candida albicans infections[J].Mem Inst Oswaldo Cruz,2015,110(1):75-78.
    [24] Badejo AM Jr,Nossaman VE,Pankey EA,et al.Pulmonary and systemic vasodilator responses to the soluble guanylyl cyclase stimulator,BAY 41-8543,are modulated by nitric oxide[J].Am J Physiol Heart Circ Physiol,2010,299(4):H1153-H1159.
    [25] Watts JA,Gellar MA,Fulkerson MB,et al.A soluble guanylate cyclase stimulator,BAY 41-8543,preserves right ventricular function in experimental pulmonary embolism[J].Pulm Pharmacol Ther,2013,26(2):205-211.
    [26] Hoffmann LS,Etzrodt J,Willkomm L,et al.Stimulation of soluble guanylyl cyclase protects against obesity by recruiting brown adipose tissue[J].Nat Commun,2015,6:7235.
    [27] Mittendorf J, Weigand S, Alonso-Alija C, et al. Discovery of riociguat(BAY 63-2521):a potent,oral stimulator of soluble guanylate cyclase for the treatment of pulmonary hypertension[J].ChemMedChem,2009,4(5):853-865.
    [28] Lang M,Kojonazarov B,Weissmann N,et al.The soluble guanylate cyclase stimulator riociguat ameliorates pulmonary hypertension induced by hypoxia and SU5416 in rats[J].PLoS One,2012,7(8):e43433.
    [29] Stasch JP, Evgenov OV. Soluble guanylate cyclase stimulators inpulmonary hypertension[J].Handb Exp Pharmacol,2013,218:279-313.
    [30] Ghofrani HA,Galiè N,Grimminger F,et al.Riociguat for the treatment of pulmonary arterial hypertension[J].N Engl J Med,2013,369(4):330-340.
    [31] Dees C,Beyer C,Distler A,et al.Stimulators of soluble guanylate cyclase(sGC)inhibit experimental skin fibrosis of different aetiologies[J].Ann Rheum Dis,2015,74(8):1621-1625.
    • 相关文章
    • 施引文献
    • 资源附件(0)
计量
  • 文章访问数:  1355
  • HTML全文浏览量:  12
  • PDF下载量:  5643
  • 被引次数: 0
出版历程
  • 刊出日期:  2016-10-24

目录

摘要
HTML全文
    参考文献(31)
    相关文章
    施引文献
    资源附件(0)

    /

    返回文章
    返回

    版权所有：《中国药科大学学报》编辑部苏ICP备05007142号

    地址：江苏省南京市鼓楼区童家巷24号（210009）电话: 025-83271566E-mail: xuebao@cpu.edu.cn

    本系统由 北京仁和汇智信息技术有限公司 开发  百度统计

    访问量：336244

    x 关闭 永久关闭